<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36535289</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1678-4227</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Arquivos de neuro-psiquiatria</Title><ISOAbbreviation>Arq Neuropsiquiatr</ISOAbbreviation></Journal><ArticleTitle>Fatigue in amyotrophic lateral sclerosis and correlated factors.</ArticleTitle><Pagination><StartPage>1045</StartPage><EndPage>1051</EndPage><MedlinePgn>1045-1051</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0042-1758563</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that leads to muscle weakness and paralysis. Fatigue is a disabling symptom, frequently reported in ALS, but remains under-investigated in this population. Thus, an accurate investigation of this symptom and possible associated factors in this clinical condition is needed to assist in the establishment of an adequate treatment approach.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the presence of fatigue in individuals with ALS and possible factors correlated with this symptom.</AbstractText><AbstractText Label="METHODS">Sixty-five individuals with sporadic ALS participated in the present study. Demographic, clinical, and functional aspects were investigated. Evaluations involved the Fatigue Severity Scale (FSS), ALS Functional Scale (ALSRFS-R), and Quality of Life (QoL) questionnaire (ALSAQ-40). Descriptive and correlation analyses were performed with SPSS statistical program for Windows version 19.0 (IBM Corp., Armonk, NY, USA).</AbstractText><AbstractText Label="RESULTS">Among the 65 individuals evaluated, 44.6% (<i>n</i>&#x2009;=&#x2009;29) presented fatigue based on the FSS. The mean fatigue intensity was 5.4&#x2009;&#xb1;&#x2009;1.2 and only 10.4% used a specific medication for fatigue. Differences between the groups with and without fatigue were found regarding sex (<i>p</i>&#x2009;=&#x2009;0.049), pain intensity (<i>p</i>&#x2009;=&#x2009;0.026), functioning (<i>p</i>&#x2009;=&#x2009;0.004), disease severity (<i>p</i>&#x2009;=&#x2009;0.029), and QoL (<i>p</i>&#x2009;=&#x2009;0.000). Fatigue was correlated with pain intensity (r&#x2009;=&#x2009;0.425; <i>p</i>&#x2009;=&#x2009;0.001), muscle strength (r&#x2009;=&#x2009;- 0.356; <i>p</i>&#x2009;=&#x2009;0.004), functioning (r&#x2009;=&#x2009;- 0.363; <i>p</i>&#x2009;=&#x2009;0.003), and QoL (r&#x2009;=&#x2009;0.481; <i>p</i>&#x2009;=&#x2009;0.000). No correlations were found with age, time since diagnosis, cramps, or other mobility parameters.</AbstractText><AbstractText Label="CONCLUSIONS">Fatigue is a common symptom among individuals with ALS and may be present in all stages of the disease. This symptom was correlated with worse functioning, poorer QoL, greater pain intensity, disease severity, muscle weakness, and the female sex in individuals with ALS.</AbstractText><CopyrightInformation>Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alencar</LastName><ForeName>Mariana Asmar</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-3881-5283</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Bruna Laura</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0001-7433-5522</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangel</LastName><ForeName>Marcela Ferreira de Andrade</ForeName><Initials>MFA</Initials><Identifier Source="ORCID">0000-0002-0897-2133</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdo</LastName><ForeName>Juliana Silva</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-5023-2294</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Rayane Alves Pereira de</ForeName><Initials>RAP</Initials><Identifier Source="ORCID">0000-0002-4241-0185</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ara&#xfa;jo</LastName><ForeName>Caroline Martins de</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-8866-0374</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Neuroci&#xea;ncia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Leonardo Cruz de</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0001-5027-9722</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Neuroci&#xea;ncia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Medicina Interna, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Gisele de C&#xe1;ssia</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0001-7829-9493</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Minas Gerais, Departamento de Fisioterapia, Belo Horizonte MG, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Fadiga na esclerose lateral amiotr&#xf3;fica e fatores correlacionados.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arq Neuropsiquiatr</MedlineTA><NlmUniqueID>0125444</NlmUniqueID><ISSNLinking>0004-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">&#x2003;Esclerose lateral amiotr&#xf3;fica (ELA) &#xe9; uma doen&#xe7;a neurodegenerativa fatal que leva &#xe0; fraqueza muscular e paralisia. Fadiga &#xe9; um sintoma incapacitante, frequentemente relatado na ELA, mas permanece pouco investigado nessa popula&#xe7;&#xe3;o. Assim, uma investiga&#xe7;&#xe3;o acurada deste sintoma e dos poss&#xed;veis fatores associados &#xe9; necess&#xe1;ria para auxiliar em uma abordagem terap&#xea;utica adequada.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">&#x2003;Investigar a presen&#xe7;a de fadiga em indiv&#xed;duos com ELA e poss&#xed;veis fatores correlacionados a este sintoma. M&#xe9;TODOS: &#x2003;Participaram 65 indiv&#xed;duos com ELA espor&#xe1;dica. Aspectos demogr&#xe1;ficos, cl&#xed;nicos e funcionais foram investigados. Foram utilizadas: Escala de Severidade de Fadiga (FSS, na sigla em ingl&#xea;s), Escala Funcional de ELA (ALSRFS-R, na sigla em ingl&#xea;s) e question&#xe1;rio de Qualidade de Vida (QV) (ALSAQ-40, na sigla em ingl&#xea;s). An&#xe1;lises descritivas e de correla&#xe7;&#xe3;o foram realizadas no programa SPSS para Windows vers&#xe3;o 19.0 (IBM Corp., Armonk, NY, USA).</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">&#x2003;Dos 65 indiv&#xed;duos avaliados, 44,6% (<i>n</i>&#x2009;=&#x2009;29) apresentaram fadiga pela FSS. A intensidade da fadiga foi 5,4&#x2009;&#xb1;&#x2009;1,2 e apenas 10,4% usavam medicamento espec&#xed;fico para fadiga. Diferen&#xe7;as entre os grupos com e sem fadiga foram encontradas em rela&#xe7;&#xe3;o ao sexo (<i>p</i>&#x2009;=&#x2009;0,049), intensidade da dor (<i>p</i>&#x2009;=&#x2009;0,026), funcionalidade (<i>p</i>&#x2009;=&#x2009;0,004), gravidade da doen&#xe7;a (<i>p</i>&#x2009;=&#x2009;0,029) e QV (<i>p</i>&#x2009;=&#x2009;0,000). A fadiga foi correlacionada com a intensidade da dor (r&#x2009;=&#x2009;0,425; <i>p</i>&#x2009;=&#x2009;0,001), for&#xe7;a muscular (r&#x2009;=&#x2009;- 0,356; <i>p</i>&#x2009;=&#x2009;0,004), funcionalidade (r&#x2009;=&#x2009;- 0,363; <i>p</i>&#x2009;=&#x2009;0,003) e QV (<i>r</i>&#x2009;=&#x2009;0,481; <i>p</i>&#x2009;=&#x2009;0,000). N&#xe3;o foram encontradas correla&#xe7;&#xf5;es com idade, tempo de diagn&#xf3;stico, c&#xe3;ibras ou outros par&#xe2;metros de mobilidade. CONCLUS&#xf5;ES: &#x2003;A fadiga &#xe9; um sintoma comum entre os indiv&#xed;duos com ELA e pode estar presente em todos os est&#xe1;gios da doen&#xe7;a. Este sintoma estava correlacionado &#xe0; pior funcionalidade, pior QV, gravidade, intensidade da dor, fraqueza muscular e sexo feminino em indiv&#xed;duos com ELA.</AbstractText><CopyrightInformation>Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></OtherAbstract><CoiStatement>The authors have no conflict of interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>19</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36535289</ArticleId><ArticleId IdType="pmc">PMC9770075</ArticleId><ArticleId IdType="doi">10.1055/s-0042-1758563</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oskarsson B, Gendron T F, Staff N P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 2018;93(11):1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg L H, Kiernan M C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Silva J P, Santiago J&#xfa;nior J B, Dos Santos E L, de Carvalho F O, de Fran&#xe7;a Costa I MP, Mendon&#xe7;a D MF. Quality of life and functional independence in amyotrophic lateral sclerosis: A systematic review. Neurosci Biobehav Rev. 2020;111:1&#x2013;11. doi: 10.1016/j.neubiorev.2019.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.12.032</ArticleId><ArticleId IdType="pubmed">31917162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou J S. Fatigue in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008;19(03):533&#x2013;543, ix. doi: 10.1016/j.pmr.2008.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmr.2008.02.001</ArticleId><ArticleId IdType="pubmed">18625414</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;kerblom Y, Jakobsson Larsson B, Zetterberg L, &#xc5;senl&#xf6;f P. The multiple faces of pain in motor neuron disease: a qualitative study to inform pain assessment and pain management. Disabil Rehabil. 2020;42(15):2123&#x2013;2132. doi: 10.1080/09638288.2018.1555615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2018.1555615</ArticleId><ArticleId IdType="pubmed">31014130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons C, Pagnini F, Friede T, Young C A. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2018;1(01):CD011005. doi: 10.1002/14651858.CD011005.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011005.pub2</ArticleId><ArticleId IdType="pmc">PMC6494184</ArticleId><ArticleId IdType="pubmed">29293261</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter G T, Weiss M D, Lou J S. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care. 2005;22(01):55&#x2013;59. doi: 10.1177/104990910502200112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/104990910502200112</ArticleId><ArticleId IdType="pubmed">15736608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez C, Piemonte M E, Callegaro D, Da Silva H C. Fatigue in amyotrophic lateral sclerosis: frequency and associated factors. Amyotroph Lateral Scler. 2008;9(02):75&#x2013;80. doi: 10.1080/17482960701642502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701642502</ArticleId><ArticleId IdType="pubmed">17924237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons C, Thornton E, Ealing J.The impact of fatigue and psychosocial variables on quality of life for patients with motor neuron disease Amyotroph Lateral Scler Frontotemporal Degener 201314(7-8):537&#x2013;545.10.3109/21678421.2013.799700</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.799700</ArticleId><ArticleId IdType="pubmed">23725553</ArticleId></ArticleIdList></Reference><Reference><Citation>Young C A, Ealing J, McDermott C.The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease Amyotroph Lateral Scler Frontotemporal Degener 201920(5-6):317&#x2013;327.10.1080/21678421.2019.1615951</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1615951</ArticleId><ArticleId IdType="pubmed">31116037</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhiney M C, Rabkin J G, Gordon P H, Goetz R, Mitsumoto H. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry. 2009;80(10):1146&#x2013;1149. doi: 10.1136/jnnp.2008.163246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.163246</ArticleId><ArticleId IdType="pubmed">19762902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Coco D, La Bella V. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2012;19(05):760&#x2013;763. doi: 10.1111/j.1468-1331.2011.03637.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03637.x</ArticleId><ArticleId IdType="pubmed">22233269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Sansone V A. Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. J Neurol. 2016;263(01):52&#x2013;60. doi: 10.1007/s00415-015-7924-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7924-z</ArticleId><ArticleId IdType="pubmed">26477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo F O, Junior W M, Speciali J G, Sobreira C FDR. PND66 Cross-Cultural Adaptation and Validation of the Brazilian Version of the Fatigue Severity Scale (FSS) Value Health. 2011;14(07):A329&#x2013;A330. doi: 10.1016/j.jval.2011.08.532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2011.08.532</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes K, Pereira C, Pavan K, Val&#xe9;rio B C. Cross-cultural adaptation and validation of als Functional Rating Scale-Revised in Portuguese language. Arq Neuropsiquiatr. 2010;68(01):44&#x2013;47. doi: 10.1590/s0004-282X2010000100010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0004-282X2010000100010</ArticleId><ArticleId IdType="pubmed">20339651</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng D, Ou R, Miao X.Patients' self-perceived burden, caregivers' burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study J Clin Nurs 201726(19-20):3188&#x2013;3199.10.1111/jocn.13667</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.13667</ArticleId><ArticleId IdType="pubmed">27874996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandstedt P, Johansson S, Ytterberg C, Ingre C, Holmqvist L W, Kierkegaard M. Predictors of health-related quality of life in people with amyotrophic lateral sclerosis. J Neurol Sci. 2016;370:269&#x2013;273. doi: 10.1016/j.jns.2016.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.09.034</ArticleId><ArticleId IdType="pubmed">27772773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshiri H, Fatehi F, Abolfazli R. Trends of quality of life changes in amyotrophic lateral sclerosis patients. J Neurol Sci. 2016;368:35&#x2013;40. doi: 10.1016/j.jns.2016.06.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.056</ArticleId><ArticleId IdType="pubmed">27538598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch F, Skudlarek A, Berndt J, Kornhuber M E. Characteristics of pain in amyotrophic lateral sclerosis. Brain Behav. 2015;5(03):e00296. doi: 10.1002/brb3.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.296</ArticleId><ArticleId IdType="pmc">PMC4309879</ArticleId><ArticleId IdType="pubmed">25642388</ArticleId></ArticleIdList></Reference><Reference><Citation>Paternostro-Sluga T, Grim-Stieger M, Posch M. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 2008;40(08):665&#x2013;671. doi: 10.2340/16501977-0235.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-0235</ArticleId><ArticleId IdType="pubmed">19020701</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavan K, Marangoni B E, Zinezzi M O. Validation of the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) scale in the Portuguese language. Arq Neuropsiquiatr. 2010;68(01):48&#x2013;51. doi: 10.1590/s0004-282X2010000100011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0004-282X2010000100011</ArticleId><ArticleId IdType="pubmed">20339652</ArticleId></ArticleIdList></Reference><Reference><Citation>Portney L G, Watkins M P. 3a ed. NJ: Pearson Education; 2015. Foundations of clinical research: applications to practice.</Citation></Reference><Reference><Citation>Nicholson K, Murphy A, McDonnell E. Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve. 2018;57(01):20&#x2013;24. doi: 10.1002/mus.25712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25712</ArticleId><ArticleId IdType="pubmed">28561886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Community Health. 1992;46(02):92&#x2013;97. doi: 10.1136/jech.46.2.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.46.2.92</ArticleId><ArticleId IdType="pmc">PMC1059513</ArticleId><ArticleId IdType="pubmed">1583440</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S A, Simmons Z. Symptom management in amyotrophic lateral sclerosis: We can do better. Muscle Nerve. 2018;57(01):1&#x2013;3. doi: 10.1002/mus.25740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25740</ArticleId><ArticleId IdType="pmc">PMC5749258</ArticleId><ArticleId IdType="pubmed">28681465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons C J, Mills R J, Thornton E W. Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND) Health Qual Life Outcomes. 2011;9:101. doi: 10.1186/1477-7525-9-101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-9-101</ArticleId><ArticleId IdType="pmc">PMC3282643</ArticleId><ArticleId IdType="pubmed">22107756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>